Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. The findings add to a growing body of evidence suggesting that CBD alone may not provide clinically meaningful pain relief in this population. Patients and clinicians should weigh these results carefully when considering CBD as a standalone treatment for fibromyalgia.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides much-needed rigorous evidence to support or refute the widespread off-label use of CBD for fibromyalgia pain management, addressing a significant evidence gap in clinical practice. The results will inform treatment guidelines and help clinicians make evidence-based decisions regarding CBD as a potential therapeutic option for this difficult-to-treat chronic pain condition. Additionally, the safety data generated will clarify the tolerability profile of CBD in fibromyalgia patients, which is essential for clinical decision-making given the current lack of standardized dosing and safety data in this population.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This randomised controlled trial provides valuable evidence on CBD efficacy in fibromyalgia, a condition where patients often seek cannabinoid therapies due to limited conventional options, yet the single-centre design and likely modest sample size warrant cautious interpretation before broadening clinical application. The study’s relevance is further complicated by fibromyalgia’s heterogeneous pathophysiology and high placebo response rates, which may obscure genuine CBD effects or conversely inflate them depending on baseline expectations and measurement tools used. Notably, the absence of active comparators means we cannot determine whether CBD outperforms established pharmacotherapies like pregabalin or SNRIs, limiting its positioning in treatment algorithms. In clinical practice, this evidence suggests CBD may have a role in fibromyalgia management, particularly for patients who decline or cannot tolerate standard agents, but practitioners should set realistic expectations with patients, monitor for drug interactions (especially with CYP3A4 substrates), and remain alert to the gap between this single trial’s findings and
|